急性至慢性肝衰竭:迈向共识的步骤
Loredana Gabriela Goran1,2, Florina Alexandra Liţă Cofaru1,3, Carmen Fierbinţeanu-Braticevici1,2
1Emergency University Hospital Bucharest, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Diagnostics (Basel, Switzerland)
|March 28, 2025
概括
急性至慢性肝衰竭 (ACLF) 是一种严重的疾病,死亡率高. 对于有效的治疗,就其定义和管理达成共识至关重要,因为目前的理解和方法仍在发展.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内部医学 内部医学
- 关键护理医学 关键护理医学
背景情况:
- 急性至慢性肝衰竭 (ACLF) 是一种严重的临床综合征.
- 它与高短期死亡率有关.
- 对ACLF的国际定义和诊断标准仍然不一致.
研究的目的:
- 强调需要对ACLF制定统一的定义和诊断标准.
- 强调了解ACLF的潜在机制和炎症反应的重要性.
- 强调需要为ACLF制定具体的管理策略.
主要方法:
- 审查现有的文献和ACLF的定义.
- 分析ACLF中沉因素和全身炎症的作用.
- 讨论当前的诊断和管理挑战.
主要成果:
- 自2013年以来,多个国际组织提出了ACLF的定义.
- 在标准化诊断标准上缺乏共识.
- 系统性炎症和沉因素被认为是ACLF的关键贡献者.
结论:
- 目前,ACLF缺乏普遍接受的定义和诊断标准.
- 需要对ACLF机制进行进一步的研究.
- 迫切需要为ACLF的诊断和管理制定共识,以改善患者的治疗结果.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...


